The high-end cellomics market revenue totaled US$ 325.1 million in 2023, according to Future Market Insights (FMI) study. The overall sales of high-end cellomics are expected to reach US$ 639.2 million by 2033, capturing a CAGR of 7% from 2023 to 2033.
Recent developments in drug discovery and high-end cellomics have augmented pressure at the strategic points along the drug discovery pipeline, auguring well for the market’s future trends. The rising need to determine and study toxicity levels in the initial phase of drug discovery is driving market growth.
How does the Development of Advanced Imaging Systems Augment High-end Cellomics Market Growth?
| Attributes | Details |
|---|---|
| High-end Cellomics Market Value 2023 | US$ 325.1 million |
| Estimated High-end Cellomics Market Value 2033 | US$ 639.2 million |
| CAGR 2023 to 2033 | 7% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to Future Market Insights (FMI), the sales of high-end cellomics have expanded at a CAGR of 4.9% from 2018 to 2022.
The demand for effective screening methods and techniques has surged in the last decade due to the rising prevalence of several genetic disorders and neurological diseases. This had a positive impact on the high-end cellomics market. Furthermore, initiatives undertaken by governments to promote advanced biotechnology research increase the installation of high-end cellomics instruments for drug discovery applications.
Cities of India such as Bangalore, Pune, Hyderabad, and Tamil Nadu have well-established biotechnology research infrastructures recognized globally, which is predicted to soar the demand for high-end research instruments.
Apart from India, China, and the United States of America, the governments of Japan, Brazil, the United Kingdom, and Australia are supporting their domestic biotechnology and bioscience industry through similar initiatives, shaping the high-end cellomics market demand analysis.
Principal Consultant
High-end Cellomics Market:
| Attributes | High-end Cellomics Market |
|---|---|
| CAGR (2023 to 2033) | 7% |
| Market Value (2033) | US$ 639.2 million |
| Opportunity | The growing interest in outsourcing services is anticipated to positively drive the sales of high-end cellomics systems, which in turn provides a key opportunity for market growth. |
| Key Trends | Increasing integration of artificial intelligence (AI) and machine learning technologies. |
Specific Imaging Solution Market:
| Attributes | Specific Imaging Solution Market |
|---|---|
| CAGR (2023 to 2033) | 6.5% |
| Market Value (2033) | US$ 756.3 million |
| Opportunity | The imaging process is predicted to be automated and streamlined through the use of software-based value-added services powered by the Internet of Things (IoT) and data analytics, which can provide manufacturers with a key market opportunity. |
| Key Trends | Key market trends include an increase in chronic disease diagnoses, product technical breakthroughs, and corporate expansions through partnerships. |
Molecular Imaging Market:
| Attributes | Molecular Imaging Market |
|---|---|
| CAGR (2023 to 2033) | 5.4% |
| Market Value (2033) | US$ 7.6 billion |
| Opportunity | The molecular imaging market is likely to witness profitable opportunities owing to the development of AI-based medical equipment. |
| Key Trends | The rise of hybrid imaging combines multiple imaging modalities for comprehensive and accurate diagnostic information. |
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
In 2022, the United States of America’s high-end cellomics market accounted for over 28.5% value share in North America.
Demand in the United States of America is primarily driven by a strong regional economy, the presence of refined research and healthcare facilities, and improved attention to overall health and well-being.
The country's supportive regulatory environment and access to funding further contribute to its position as a leading market for high-end cellomics.
Germany accounted for a 6.5% value share in 2022. Germany’s high-end cellomics market is projected to fare positively in the coming years.
Growing capital and venture investments for cellular research, technological developments in high-end cellomics solutions, cost restraint in pharma research and development, and the presence of key players have resulted in the high growth of Germany’s market.
What are the Factors Supporting High-end Cellomics Sales in Australia?
Australia’s market is anticipated to exhibit a 5.5% CAGR during the forecast period. The rising prevalence of neurodegenerative diseases such as Alzheimer’s and Parkinson’s is one of the key factors driving the market growth. Similarly, the growing geriatric population is supplementing market growth in Australia.
The market in India is expected to advance at 9.2% CAGR from 2023 to 2033. Research activities in the biotechnology and bioscience field are increasing notably due to government support and the availability of funds, thus increasing the demand for high-end cellomics in India.
The Government of India is offering 100% foreign direct investment for biotechnology companies that are based outside India, and the GOI is offering public-private partnerships for companies based in India.
The Department of Biotechnology has supported the biotechnology research infrastructure including high-end high content screening systems, flow cytometry, imaging microarray, and high-resolution mass spectrometry facilities in Delhi and Mumbai respectively.
The market in China is projected to exhibit a 7.7% CAGR during the forecast period and is expected to contribute significantly to the market in East Asia region. Government initiatives to spur the biotechnology industry in the region are creating growth opportunities in China.
China has included the biotechnology industry as one of the strategic priorities for development in terms of technology. Moreover, there were about 95 biotech-related deals till June 2020, drawing about US$ 12 billion deals.
In 2020, Everest Medicines Ltd and Maxwell Biosciences Co. Ltd. raised US$ 310 million in June and US$ 279 million respectively. These companies have strong oncology and immunology products in their pipelines, which require advanced instrumentation such as high-end HCS systems in the drug discovery phase for screening and compound profiling.
High-end cellomics demand in drug discovery consistently rises, registering a high share of 55.42% in 2022. Increasing support for research and development activities, particularly for rare diseases, and the growing use of informatics in drug discovery led to demand for Drug Discovery.
Pharmaceutical & biotechnology companies are currently leading the market. This sub-segment accounted for 52.03% value share in 2022.
Pharmaceutical & biotechnology companies are using this informatics software widely for pre-clinical research & development, compound screening and lead documentation, target identification, and rationalization of their drug discovery process. It becomes the key factor for propelling the growth of the Pharmaceutical & Biotechnology Companies segment.
The competitive landscape within the high-end cellomics market is structured with multiple key players vying for market share and differentiation. The market consists of several prominent companies that offer high-end cellomics solutions and compete for customers. These players may vary in terms of size, market presence, and product offerings.
Market players are actively focusing on developing high-end cellomics instruments to capitalize on the growing market opportunity. These systems have increased software data analysis and data management capabilities. Quick image acquisition and multiplexing flexibility with high-performing lasers and an improved incubation environment are some of the benefits offered by these systems.
Key Players Working in the Market:
Key Developments in the Market:
The market is valued at US$ 325.1 million in 2023.
The growth potential of the market is 7% through 2033.
The United States market relishes 28.5% market share presently.
India is anticipated to expand at a CAGR of 9.2% through 2033.
Key players are focusing on creating high-end cellomics instruments to capitalize on the expanding market.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Application 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Application, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Application, 2023 to 2033 5.3.1. Academic Research/Basic Research 5.3.2. Drug Discovery 5.3.2.1. Primary & Secondary Screening 5.3.2.2. Target Identification & Validation 5.3.2.3. Invitro Toxicity Studies 5.3.2.4. Compound Profiling 5.4. Y-o-Y Growth Trend Analysis By Application, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Application, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End-User 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By End-User, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End-User, 2023 to 2033 6.3.1. Pharmaceutical & Biotechnology Companies 6.3.2. Academic & Research Institutes 6.3.3. Independent Contract Research Organizations (CROs) 6.4. Y-o-Y Growth Trend Analysis By End-User, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By End-User, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 7.1. Introduction 7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 7.3.1. North America 7.3.2. Latin America 7.3.3. Europe 7.3.4. South Asia 7.3.5. East Asia 7.3.6. Oceania 7.3.7. MEA 7.4. Market Attractiveness Analysis By Region 8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 8.2.1. By Country 8.2.1.1. USA 8.2.1.2. Canada 8.2.2. By Application 8.2.3. By End-User 8.3. Market Attractiveness Analysis 8.3.1. By Country 8.3.2. By Application 8.3.3. By End-User 8.4. Key Takeaways 9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. Brazil 9.2.1.2. Mexico 9.2.1.3. Rest of Latin America 9.2.2. By Application 9.2.3. By End-User 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Application 9.3.3. By End-User 9.4. Key Takeaways 10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. Germany 10.2.1.2. UK 10.2.1.3. France 10.2.1.4. Spain 10.2.1.5. Italy 10.2.1.6. Rest of Europe 10.2.2. By Application 10.2.3. By End-User 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Application 10.3.3. By End-User 10.4. Key Takeaways 11. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. India 11.2.1.2. Malaysia 11.2.1.3. Singapore 11.2.1.4. Thailand 11.2.1.5. Rest of South Asia 11.2.2. By Application 11.2.3. By End-User 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Application 11.3.3. By End-User 11.4. Key Takeaways 12. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. China 12.2.1.2. Japan 12.2.1.3. South Korea 12.2.2. By Application 12.2.3. By End-User 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Application 12.3.3. By End-User 12.4. Key Takeaways 13. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. Australia 13.2.1.2. New Zealand 13.2.2. By Application 13.2.3. By End-User 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Application 13.3.3. By End-User 13.4. Key Takeaways 14. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. GCC Countries 14.2.1.2. South Africa 14.2.1.3. Israel 14.2.1.4. Rest of MEA 14.2.2. By Application 14.2.3. By End-User 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Application 14.3.3. By End-User 14.4. Key Takeaways 15. Key Countries Market Analysis 15.1. USA 15.1.1. Pricing Analysis 15.1.2. Market Share Analysis, 2022 15.1.2.1. By Application 15.1.2.2. By End-User 15.2. Canada 15.2.1. Pricing Analysis 15.2.2. Market Share Analysis, 2022 15.2.2.1. By Application 15.2.2.2. By End-User 15.3. Brazil 15.3.1. Pricing Analysis 15.3.2. Market Share Analysis, 2022 15.3.2.1. By Application 15.3.2.2. By End-User 15.4. Mexico 15.4.1. Pricing Analysis 15.4.2. Market Share Analysis, 2022 15.4.2.1. By Application 15.4.2.2. By End-User 15.5. Germany 15.5.1. Pricing Analysis 15.5.2. Market Share Analysis, 2022 15.5.2.1. By Application 15.5.2.2. By End-User 15.6. UK 15.6.1. Pricing Analysis 15.6.2. Market Share Analysis, 2022 15.6.2.1. By Application 15.6.2.2. By End-User 15.7. France 15.7.1. Pricing Analysis 15.7.2. Market Share Analysis, 2022 15.7.2.1. By Application 15.7.2.2. By End-User 15.8. Spain 15.8.1. Pricing Analysis 15.8.2. Market Share Analysis, 2022 15.8.2.1. By Application 15.8.2.2. By End-User 15.9. Italy 15.9.1. Pricing Analysis 15.9.2. Market Share Analysis, 2022 15.9.2.1. By Application 15.9.2.2. By End-User 15.10. India 15.10.1. Pricing Analysis 15.10.2. Market Share Analysis, 2022 15.10.2.1. By Application 15.10.2.2. By End-User 15.11. Malaysia 15.11.1. Pricing Analysis 15.11.2. Market Share Analysis, 2022 15.11.2.1. By Application 15.11.2.2. By End-User 15.12. Singapore 15.12.1. Pricing Analysis 15.12.2. Market Share Analysis, 2022 15.12.2.1. By Application 15.12.2.2. By End-User 15.13. Thailand 15.13.1. Pricing Analysis 15.13.2. Market Share Analysis, 2022 15.13.2.1. By Application 15.13.2.2. By End-User 15.14. China 15.14.1. Pricing Analysis 15.14.2. Market Share Analysis, 2022 15.14.2.1. By Application 15.14.2.2. By End-User 15.15. Japan 15.15.1. Pricing Analysis 15.15.2. Market Share Analysis, 2022 15.15.2.1. By Application 15.15.2.2. By End-User 15.16. South Korea 15.16.1. Pricing Analysis 15.16.2. Market Share Analysis, 2022 15.16.2.1. By Application 15.16.2.2. By End-User 15.17. Australia 15.17.1. Pricing Analysis 15.17.2. Market Share Analysis, 2022 15.17.2.1. By Application 15.17.2.2. By End-User 15.18. New Zealand 15.18.1. Pricing Analysis 15.18.2. Market Share Analysis, 2022 15.18.2.1. By Application 15.18.2.2. By End-User 15.19. GCC Countries 15.19.1. Pricing Analysis 15.19.2. Market Share Analysis, 2022 15.19.2.1. By Application 15.19.2.2. By End-User 15.20. South Africa 15.20.1. Pricing Analysis 15.20.2. Market Share Analysis, 2022 15.20.2.1. By Application 15.20.2.2. By End-User 15.21. Israel 15.21.1. Pricing Analysis 15.21.2. Market Share Analysis, 2022 15.21.2.1. By Application 15.21.2.2. By End-User 16. Market Structure Analysis 16.1. Competition Dashboard 16.2. Competition Benchmarking 16.3. Market Share Analysis of Top Players 16.3.1. By Regional 16.3.2. By Application 16.3.3. By End-User 17. Competition Analysis 17.1. Competition Deep Dive 17.1.1. Thermo Fisher Scientific Inc. 17.1.1.1. Overview 17.1.1.2. Product Portfolio 17.1.1.3. Profitability by Market Segments 17.1.1.4. Sales Footprint 17.1.1.5. Strategy Overview 17.1.1.5.1. Marketing Strategy 17.1.2. GE Healthcare 17.1.2.1. Overview 17.1.2.2. Product Portfolio 17.1.2.3. Profitability by Market Segments 17.1.2.4. Sales Footprint 17.1.2.5. Strategy Overview 17.1.2.5.1. Marketing Strategy 17.1.3. BD Biosciences 17.1.3.1. Overview 17.1.3.2. Product Portfolio 17.1.3.3. Profitability by Market Segments 17.1.3.4. Sales Footprint 17.1.3.5. Strategy Overview 17.1.3.5.1. Marketing Strategy 17.1.4. Olympus Corporation 17.1.4.1. Overview 17.1.4.2. Product Portfolio 17.1.4.3. Profitability by Market Segments 17.1.4.4. Sales Footprint 17.1.4.5. Strategy Overview 17.1.4.5.1. Marketing Strategy 17.1.5. PerkinElmer Inc. 17.1.5.1. Overview 17.1.5.2. Product Portfolio 17.1.5.3. Profitability by Market Segments 17.1.5.4. Sales Footprint 17.1.5.5. Strategy Overview 17.1.5.5.1. Marketing Strategy 17.1.6. Merck KGaA 17.1.6.1. Overview 17.1.6.2. Product Portfolio 17.1.6.3. Profitability by Market Segments 17.1.6.4. Sales Footprint 17.1.6.5. Strategy Overview 17.1.6.5.1. Marketing Strategy 17.1.7. Carl Zeiss AG 17.1.7.1. Overview 17.1.7.2. Product Portfolio 17.1.7.3. Profitability by Market Segments 17.1.7.4. Sales Footprint 17.1.7.5. Strategy Overview 17.1.7.5.1. Marketing Strategy 17.1.8. Danaher Corporation 17.1.8.1. Overview 17.1.8.2. Product Portfolio 17.1.8.3. Profitability by Market Segments 17.1.8.4. Sales Footprint 17.1.8.5. Strategy Overview 17.1.8.5.1. Marketing Strategy 17.1.9. Bio-Rad Laboratories, Inc. 17.1.9.1. Overview 17.1.9.2. Product Portfolio 17.1.9.3. Profitability by Market Segments 17.1.9.4. Sales Footprint 17.1.9.5. Strategy Overview 17.1.9.5.1. Marketing Strategy 17.1.10. Agilent Technologies, Inc. 17.1.10.1. Overview 17.1.10.2. Product Portfolio 17.1.10.3. Profitability by Market Segments 17.1.10.4. Sales Footprint 17.1.10.5. Strategy Overview 17.1.10.5.1. Marketing Strategy 18. Assumptions & Acronyms Used 19. Research Methodology
Explore Healthcare Insights
View Reports
High-end Cellomics Market
